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OBJECTIVE: This study was designed to validate an established
claims-based persistent asthma severity classiﬁcation using
clinical parameters abstracted from medical charts. METHODS:
Patients with asthma, aged 6–64 years, were selected from a
claims database (1999–2005) of a medical group practice orga-
nization located in central Massachusetts. Patients had persistent
asthma deﬁned using an established algorithm; no chronic
obstructive pulmonary disease; and at least one procedure code
for spirometry. All recorded pre-broncodilator values of FEV1 or
PEF, height, and weight were extracted from medical charts.
Patients’ asthma severity was categorized based on two methods:
an established claims-based algorithm and guidelines classiﬁca-
tion algorithm based on clinical parameters. Gamma rank cor-
relation index was used to measure the association between the
two severity categorization methods. One year total and asthma-
related costs for each severity category were also compared
between the two different approaches. RESULTS: Based on
claims-based severity classiﬁcation, 41% of 368 patients in the
study sample had mild persistent asthma, 33.7% had moderate,
and 25% had severe. Using clinical parameters (% predicted
FEV1 or PEF value), 68.2% of patients had mild, 23.9% had
moderate, and 7.9% had severe persistent asthma. The correla-
tion between the two classiﬁcation approaches was statistically
signiﬁcant (P = 0.0002). Patients with higher severity generally
had higher costs. Comparing the two classiﬁcation approaches,
patients with moderate persistent asthma using the clinical
parameters approach had signiﬁcantly higher asthma-related
direct costs ($2395) than those classiﬁed as having moderate
persistent asthma using the claims-based approach ($1604).
There were no signiﬁcant asthma-related cost differences in
mild and severe asthma categories. CONCLUSION: While more
patients were classiﬁed into higher severity level using a claims-
based classiﬁcation approach than clinical parameters, the two
classiﬁcation methods exhibited signiﬁcant association. The
claims-based algorithm can be helpful in economic studies in
asthma patients where classifying asthma severity using claims is
needed.
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OBJECTIVE: To estimate patient preferences for improvements
in onset of effect of asthma combination maintenance medica-
tions. METHODS: The Onset-of-Effect Questionnaire (OEQ) is
a self-administered instrument used to assess patient satisfaction
with how quickly asthma maintenance medications begin to
work. The OEQ elicits subject ratings for ﬁve statements: “I
could tell the medication was working” (Medication Works), “I
could feel the medication begin to work right away” (Works
Right Away), “I felt physical sensations shortly after taking the
medication that reassured me it was working” (Physical Sensa-
tions), “The medication worked as quickly as my rescue medi-
cation” (Rescue), and “I was satisﬁed with how quickly I felt the
medication begin to work” (Satisﬁed). Asthma patients,18 years
and older, currently using combination maintenance therapy,
completed an online survey instrument that included 10 stated-
choice trade-off tasks. Subjects chose among pairs of hypotheti-
cal medication alternatives, each deﬁned by responses by “people
like you” to the ﬁve OEQ statements and monthly out-of-pocket
cost, or their current treatment. We used mixed-logit methods
to estimate dollar value-to-patient (VTP) per month for
various improvements in maintenance-medication onset of effect.
RESULTS: A total of 509 subjects completed the survey.
Responses demonstrated a high level of internal validity. “Satis-
ﬁed” was the most important attribute and “Physical Sensations”
the least important attribute. Improvement from “Strongly Dis-
agree” to “Strongly Agree” on Works Right Away was preferred
by 62% (95%CI: 57–67%) of patients. Improvement from
“Strongly Disagree” to “Strongly Agree” on Satisﬁed was pre-
ferred by, 80% (95% CI: 75–85%) of patients with a mean VTP
(95% CI) of $20 ($17–$24). CONCLUSION: The results of this
study demonstrate that onset of effect, particularly patients’
ability to feel the medication begin to work right away and
patients’ satisfaction with how quickly they feel the medication
being to work, are of signiﬁcant value to asthma patients.
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OBJECTIVE: To determine if differences in perceived onset of
effect (OE) in asthma patients were clinically meaningful from
the perspective of clinicians. METHODS: Data from two clinical
trials (SD-039-0716 and SD-039-0717) of asthmatic patients
randomized to either budesonide/formoterol pMDI or placebo
were utilized in a Delphi consensus approach to identify a thresh-
old for clinically important differences in patient-perceived OE
within the context of the trials. Twelve community-based clini-
cians, including 3 allergists, 3 pulmonologists, 3 general practi-
tioners, and 3 nurses, who spent at least 50% of their time in
clinical practice and treated at least 3 patients with asthma per
week, were recruited to participate on the Delphi panel. Panelists
were asked to determine: 1) whether results of patient-perceived
OE were clinically meaningful; 2) the minimum acceptable dif-
ference between active and placebo response, assuming a 25%
placebo response; and 3) the maximum acceptable placebo effect.
The panel participated in two rounds of the Delphi process.
RESULTS: There was unanimity from panelists that results from
the clinical trials whereby a signiﬁcantly larger percentage of
patients (69% and 75% for moderate-to-severe and mild-to-
moderate asthma patients, respectively) treated with budesonide/
formoterol pMDI reported that they could feel their medication
begin to work right away compared to placebo (23% and 26%
for moderate-to-severe and mild-to-moderate asthma patients,
respectively) were clinically meaningful. The consensus results
for minimum active treatment response with a 25% placebo
effect ranged from 50% to 70%, while the consensus for
maximum placebo effect ranged from 30% to 40% for patient-
perceived OE. CONCLUSION: Differences in perceived OE
between asthma patients taking budesonide/formoterol pMDI
and those taking placebo were considered clinically meaningful
by the panel.
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